
|Videos|May 2, 2022
A discourse in clinical study timelines and the need for acceleration in retina research
Author(s)David Hutton, Emily Kaiser Maharjan
Dr. David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.
Advertisement
David Hutton, executive editor of Ophthalmology Times®, sits down with David Bingaman, DVM, PhD, Chief Development Officer of Ora Clinical to discuss the need to accelerate clinical trials and increase investments in retina research. Dr. Bingaman also discusses Ora Clinical’s presence at ARVO 2022.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
FLORetina 2025: Rajvardhan Azad on bridging global gaps in ROP care
2
FLORetina 2025: Multimodal deep learning for CKD diagnosis using retinal images and urine dipstick data
3
FLORetina 2025: Fibrosis, a limiting factor in visual acuity outcomes in neovascular AMD
4
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
5













































